India secures deal for 30 crore Biological-E Covid-19 vaccine doses
Follow The Hawk on Google News+ FollowAdvertisement

New Delhi: India's government said on Thursday it has inked a deal with domestic vaccine maker Biological-E for 30 crore Covid-19 vaccine doses for Rs 1,500 crore, the first such order for unapproved shots.
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
Advertisement
Biological E., which also has a separate deal to produce about 60 crore doses of Johnson & Johnson's Covid-19 shot annually, said on Tuesday it entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA Covid-19 vaccine in India.
Also readFSSAI to initiate action against Bisleri over unsafe water sample
Read | Covid-19 | Serum Institute of India seeks indemnity protection: Report
Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval.
Advertisement
India, the world's second-most populous country, has suffered a disastrous second wave of infections that is only now abating. Health experts say India needs to carry out mass vaccination of its 130 crore people to reduce the impact of subsequent waves.
Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead
Prime Minister Narendra Modi's government has drawn criticism for a slow vaccine rollout even though India is one of the world's biggest manufacturers of doses.
Earlier in May, Biological-E Managing Director Mahima Datla had told Reuters that the company plans to produce 7.5 crore to 8 crore doses a month from August.
—Reuters
Get The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








